CPhI Annual report forecasts double digit ADC approvals Therapeutic ADC market expected to reach $4B by 2023
Madrid, 9th October 2018: The global ADC therapeutics market is expected to grow to $4bn by 2023, with double digit approvals within 3-years, according to a new analysis in the CPhI Annual Report – the complete findings of which were released live at CPhI Worldwide in Madrid (9-11, October 2018).
CPhI Annual Report expert Vivek Sharma, CEO of Piramal Pharma Solutions, expects the global market for ADCs to grow at around 19% CAGR between 2017 and 2030 and reach an estimated value of $4 billion in the next five years, with 17 drugs that are either approved or in late stages of clinical development, catalysing such growth.
“The last few years have seen a progressive evolution of targets from first to second and third generation Antibody Drug Conjugates (ADCs), which is now accelerating growth as new compounds are more targeted, more druggable and potentially have a better chance for approval.” commented Vivek Sharma
The understanding of site-specificity and homogenously